dextroamphetamine has been researched along with Basal Ganglia Diseases in 6 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of various antipsychotic drugs on the blockade of dopaminergic receptors in striatum and limbic forebrain was examined by establishing dose-response curves for the increase in HVA and for the antagonism of d-amphetamine-induced rotation in rats with unilateral lesions of the substantia nigra." | 1.25 | On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain. ( Dingell, JV; Hill, H; Robinson, SE; Setler, P; Stawarz, RJ; Sulser, F, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mena-Segovia, J | 1 |
| Giordano, M | 1 |
| Stawarz, RJ | 1 |
| Hill, H | 1 |
| Robinson, SE | 1 |
| Setler, P | 1 |
| Dingell, JV | 1 |
| Sulser, F | 1 |
| Pycock, C | 1 |
| Tarsy, D | 1 |
| Marsden, CD | 1 |
| Rigal, J | 1 |
| Savelli, A | 1 |
| Juillet, P | 1 |
| Weiner, WJ | 1 |
| Goetz, C | 1 |
| Westheimer, R | 1 |
| Klawans, HL | 1 |
| Bunney, BS | 1 |
| Aghajanian, GK | 1 |
6 other studies available for dextroamphetamine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Striatal dopaminergic stimulation produces c-Fos expression in the PPT and an increase in wakefulness.
Topics: Animals; Basal Ganglia Diseases; Cholinergic Fibers; Corpus Striatum; Dextroamphetamine; Dopamine; G | 2003 |
On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Clozapine; Corpus Striatum; D | 1975 |
Inhibition of circling behavior by neuroleptic drugs in mice with unilateral 6-hydroxydopamine lesions of the striatum.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior; Biogenic Amines; Bis(4-Methyl-1-Homopiperazi | 1975 |
[Secondary neurologic manifestations of psychotropic therapeutics. Neurophysiological approach].
Topics: Achilles Tendon; Antidepressive Agents; Basal Ganglia Diseases; Butyrophenones; Dextroamphetamine; E | 1972 |
Serotonergic and antiserotonergic influences on amphetamine-induced stereotyped behavior.
Topics: 5-Hydroxytryptophan; Acetylcholine; Animals; Basal Ganglia Diseases; Behavior, Animal; Corpus Striat | 1973 |
Proceedings: Differentiation between neuroleptic antipsychotic properties and side effects by subgroups of dopaminergic neurons.
Topics: Animals; Basal Ganglia Diseases; Depression; Dextroamphetamine; Dopamine; Feedback; Humans; Neurons; | 1974 |